Glossary of equivalent standards
Committee representation
Background of AAMI adoption of ISO 13022:2012
Foreword
Introduction
1 Scope
2 Normative references
3 Terms and definitions
4 Risk management process
Annex A (informative) - Guidance on the application
        of ISO 13022
Annex B (informative) - Graphic representation of
        the part of the risk management process for
        cell-based medical products
Annex C (normative) - Requirements for donor
        selection and testing
Annex D (informative) - Guidance for tissue procurement
Annex E (normative) - Requirements for handling of
        cells and tissue during manufacture
Annex F (normative) - Requirements for packaging and
        labeling
Annex G (informative) - Guidance for transport
Annex H (informative) - Guidance for storage
Annex I (normative) - Requirements for traceability
Annex J (normative) - Risk reduction measures related to
        contamination with viruses and other infectious
        agents such as TSE
Annex K (informative) - Guidance with regard to hazards
        caused by the tumorigenic potential of the human
        cells/tissues used for the production of medical
        products
Annex L (informative) - Guidance with regard to
        microbiological contamination
Annex M (informative) - Guidance with regard to potential
        adverse effects of non-cellular residues of
        the product
Annex N (normative) - Requirements with regard to
        potential adverse effects of the cellular components
        of a medical product
Annex O (informative) - Guidance for the characterization
        of the cellular components of a medical product
Annex P (informative) - Clinical evaluation and testing
Bibliography